Navigate Biopharma Services
Navigate Biopharma Services is recorded as a service provider in 37 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 37 trials · Latest update first
KontRASt-03: A Phase Ib/II, multicenter, open-label platform study of JDQ443 with select combinations in patients with advanced solid tumors harboring the KRAS G12C mutation
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study of BMS-986449 Alone and in Combination with Nivolumab in Participants with Advanced Solid Tumors
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
Phase I/II, open label, multicenter study of rapcabtagene autoleucel in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants with Advanced Solid Tumors
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2, open-label study to evaluate the efficacy and safety of rapcabtagene autoleucel in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase II, multi-part, five-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-center, phase 1/2 study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with Relapsing Multiple Sclerosis with breakthrough disease activity during previous treatment with a highly efficacious therapy
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-center, phase I/II study to assess safety, disease progression, and cellular kinetics following YTB323 administration in participants with non-active Progressive Multiple Sclerosis (PMS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-center, phase 1/2 study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in participants with difficult-to-treat rheumatoid arthritis and severe, refractory Sjogren's disease with organ involvement
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia (QuANTUM-Wild)
Sponsor Daiichi Sankyo Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-center, phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected Tyrosine Kinase Inhibitor (TKI) in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Navigate Biopharma Services?
The 2026-10-09 snapshot links Navigate Biopharma Services to 37 distinct CTIS trials. Recorded services include Laboratory services, PK Analysis, VCN, RCL testing, Analyzing lab to generate exploratory FIHC CD3/CD8/HLA-DP, DQ, DR/LAG3/PD1/CK-Sox10 multiplex, among 17 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Navigate Biopharma Services?
The most frequently recorded therapeutic areas are Immunology, Haematological Malignancies, Solid Tumor Oncology, Neurology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Navigate Biopharma Services conducted?
The linked trials record locations in 26 countries, including Spain, France, Italy, Germany, Belgium. These are trial locations, not confirmed office locations or countries where Navigate Biopharma Services delivered services.
What can this page tell me about Navigate Biopharma Services's trial experience?
Browse 37 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Navigate Biopharma Services. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Navigate Biopharma Services Inc.